Overview
Cognito Therapeutics is developing non-invasive sensory stimulation therapies using 40Hz gamma frequency light and sound to target the neurological mechanisms underlying Alzheimer's disease. Their OVERTURE Phase 3 clinical trial is evaluating the Cognito Therapy System for slowing cognitive and functional decline in mild-to-moderate Alzheimer's patients.
More in Cognitive Health
Latest industry news
FDA Grants De Novo Approval to Modius Spero Neuromodulation Device for PTSD
2026-09-23 · Policy
Vagus Nerve Stimulation Enters the Sports Performance Arena With New Anxiety Support Device
2026-09-22 · Product
Aurenar Raises $5.7M to Accelerate Stroke Neuromodulation Device Development
2026-09-21 · Funding
UCANACT Raises €800,000 to Advance Brain-Computer Communication Technology
2026-09-20 · Funding
Company details
Category
💭 Cognitive Health
Location
Cambridge, MA, USA
Funding
Series C · $73M+
Website
cognitotx.comListed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →